ASH 2018 Conference Review (Multiple Myeloma Focus)

Independent commentary on selected presentations has been made by Dr Henry Chan from Auckland, and Associate Professor Hang Quach from Melbourne, who attended the meeting.

Highlights include:

 - KRd ± SCT or KCd regimen for new multiple myeloma.

 - Double or single autologous SCT for new multiple myeloma.

 - Selinexor + dexamethasone in pentarefractory multiple myeloma.

 - Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.

Please login below to download this issue (PDF)